MedTrace Logo

Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers

NCT00711074 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2009-04-09

No results posted yet for this study

Summary

The purpose of this study is to determine how the body breaks down and excretes the investigational drug, AZD5672.

Conditions

Interventions

DRUG

AZD5672

single dose 200mg aqueous solution

Sponsors & Collaborators

Principal Investigators

  • Mark Layton · AstraZeneca

  • Raj Chetty · AstraZeneca

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Completion
2008-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00711074 on ClinicalTrials.gov